Becker's Healthcare December 19, 2024
Alexandra Murphy

Merck has entered into a global licensing agreement with Chinese biopharmaceutical company Hansoh Pharma to develop an oral small molecule GLP-1 receptor agonist, HS-10535.

The drug is in preclinical stages and aims to target cardiometabolic benefits, including weight reduction, according to a Dec. 18 news release from Merck....

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Pharma, Pharma / Biotech
Related Articles:
Bringing genomics closer to patients: 3 takeaways from Henry Ford Health
What are pharmacy benefit managers? A health economist explains how lack of competition drives up drug prices
How Medicare Negotiated Drug Prices Compare to Other Countries
The Fed's Warnings On Inflation Are Bad News For Biotech Startups
AI Tech Firm SandboxAQ Adds $300M to Ramp Up Development of LQMs for Drug Discovery & More

Share This Article